Abstract: A method of manufacturing an electrical device, comprising: forming a patterned inorganic liftoff layer to expose a target electrode site on a softening polymer layer, depositing an electrode layer on the inorganic liftoff layer and on the exposed target electrode site, and removing the inorganic liftoff layer by a horizontal liftoff etch to leave the electrode layer on the exposed target electrode site.

Abstract: Disclosed herein are novel cycloalka[b]heteroaryl compounds having CX3CR1/fractalkine receptor (CX3CR1) agonistic properties, pharmaceutical compositions comprising these compounds, chemical processes for preparing these compounds and their use in the treatment or prophylaxis of diseases associated with CX3CR1 receptor activity in animals, in particular humans.

Abstract: Provided is a method of making a preliposomal Annamycin lyophilizate, the composition made by the method, and the use of the composition made thereby in the treatment of cancer.

Abstract: Methods of reconstituting lyophilized Annamycin and methods of treating patients are described.

Abstract: Systems, methods, and techniques are described herein for characterizing well treatment fluids and well treatment fluid performance. For example, well treatment fluids can be characterized using microfluidic chips to determine fluid properties, with very small amounts of fluid used for the characterization process. Optical analysis and electrical conductivity analysis of well treatment fluids as they pass through different microfluidic pathways with different cross-sectional dimensions can be used to gain information about the well treatment fluid's composition, structure, and performance. In some cases, microfluidic pathways can be functionalized as a model for a wellbore and a reservoir (e.g., rock in the reservoir) to evaluate the performance of well treatment fluids by imaging the well treatment fluid as it flows into or through the functionalized model. These systems, methods, and techniques can allow for optimization of well treatment fluids prior to or during drilling or completion operations.

Abstract: Described herein are methods and systems for identifying and/or treating subjects having cancer who are more likely to respond to treatment with an inhibitor of the transcription factor HIF-2?.

Abstract: Mid-IR light emitting diodes (LEDs) based on type-II quantum dot (QD) active regions grown with monolithically integrated semiconductor metal layers are provided. These LEDs comprise layers of type-II semiconductor (e.g., InGaSb) quantum dots integrated into a pn junction diode (e.g., InAs) grown above a highly doped backplane, such as an n++ InAs backplane, all in the same epitaxial growth. Aspects described herein minimize non-radiate recombination times and significantly increase radiative recombination rates by controlling the emission of the emitting QDs in the near field of an optical metal.

Abstract: The present disclosure provides one or more amino lipids such as an amino lipids containing a sulfonic acid or sulfonic acid derivative of the formulas: wherein the variables are as defined herein. These amino lipids may be used in compositions with one or more helper lipids and a nucleic acid therapeutic agent. These compositions may be used to treat a disease or disorder such as cancer, cystic fibrosis, or other genetic diseases.

Abstract: Disclosed herein is the compound (R)-1-(4-(6-(2-(4-(3,3-difluorocyclobutoxy)-6-methylpyridin-2-yl)acetamido) pyridazin-3-yl)-2-fluorobutyl)-N-methyl-1H-1,2,3-triazole-4-carboxamide, and salt forms and polymorphs thereof demonstrating improved exposure after oral dosing. Methods of inhibition GLS1 activity in a human or animal subject are also provided.

Abstract: A method of measuring fluid flow rate is provided. The method comprises positioning a piezoelectric sensor in a fluid flow stream and measuring a voltage output from the piezoelectric sensor caused by mechanical stress from the fluid flow stream. A fluid flow rate is calculated based on the measured voltage output according to predefined relationships between the voltage output and a number physical parameters.

Abstract: Provided herein are compositions comprising multi domain peptide (MDP) hydrogels where the peptides that constitute the hydrogel have at least one N6-(1-iminoethyl)-lysine side chain. Also provided are hydrogels that further comprise a STING agonist, an immune checkpoint inhibitor, and/or an anti-cancer therapy. Also provided are methods of using such compositions in the treatment of cancer.

Abstract: Methods and systems for assisting tonally-challenged singers. A microphone can be integrated with a sound reinforcement system used in a live performance. The microphone, which can transduce the performer's voice, can serve multiple purposes such as, for example, to feed input to the natural ear and to the sound reinforcement system. The processed sound of the performer's voice (with fundamental frequency emphasized) can be mixed into the signal fed to a stage “monitor” speaker facing the performer or a headset worn by the performer.

Abstract: The present invention includes compositions and methods for treating an autoimmune disorder or a cancer in a subject in need thereof, the method comprising: administering an effective amount of a composition comprising an oligonucleotide that specifically binds a complementary sequence of the Interleukin-7 receptor (IL7R) pre-mRNA that influences splicing of exon 6, wherein the SM-ASO increases or decreases inclusion of exon 6 in IL7R pre-mRNAs and respectively decreases or increases expression of the soluble isoform of IL7R (sIL7R). In certain embodiments, the oligonucleotide is an antisense oligonucleotide (ASO), or a splice-modulating antisense oligonucleotide (SM-ASO).

Abstract: Provided herein are bispecific antibodies binding to VEGF and EGFR or VEGF and HER2, and their use in treating cancer.

Abstract: The present invention relates to compounds and methods of use thereof for treatment of certain disorders and conditions, for example brain injuries such as stroke or traumatic brain injuries.

Abstract: A method of electrochemical sensing includes providing an electrochemical sensor comprising a glassy carbon substrate and gold nanoparticles located on a surface of the glassy carbon substrate; and sensing electrochemically a compound selected from the group consisting of polyfluoroalkyl compounds or perfluoroalkyl compounds using the electrochemical sensor. PFOA quantification was performed by Square Wave Adsorptive Cathodic Stripping Voltammetry (SW-AdCSV) in test solutions with a 100-5,000 ppt concentration. The concentration has a linear relationship with the stripping current within this range. Analysis of tap and groundwater samples performed by additions method demonstrated precision and accuracy above 95%. These electrodes show stability throughout 200 cycles, and reproducibility across similarly prepared but different electrodes above 97.5%.

Abstract: Embodiments can take brain activity measurement and decode into continuous language. Embodiment can use non-invasive brain recordings, such as functional magnetic resonance imaging (fMRI) and functional near-infrared spectroscopy (fNIRS) to detect changes in blood oxygen level that are coupled to neural activity. These brain recordings can be used by a language reconstruction model that involves a neural language model to predict a next word in a sequence and an encoding model to decode the recordings into continuous language, or sequences of words.

Abstract: In some aspects, the present disclosure provides a nanoparticle composition comprising tRNA and an aminolipid delivery compound. The aminolipid delivery compound may be a dendrimer, dendron, or dendritic lipid, a polymer such as a polyamide or polyester, or a lipid with one or more hydrophobic components. In some embodiments, these compositions may be administered to a patient to treat a genetic disease or disorder such as cystic fibrosis, Duchene muscular dystrophy, or cancer.

Abstract: Described herein are methods and systems for identifying and/or treating subjects having cancer who are more likely to respond to treatment with an inhibitor of the transcription factor HIF-2?.

Abstract: The present disclosure is directed to bispecific antibodies which bind to both PD-L1 and PD-L2, and methods of using such antibodies to treat cancers, such as those that express or overexpress PD-L1, PD-L2, or both.